| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/25/2001 | WO2001005970A2 Gtp-binding protein associated factors |
| 01/25/2001 | WO2001005969A2 Electron transfer proteins |
| 01/25/2001 | WO2001005967A1 Splice variants of cd40-receptor |
| 01/25/2001 | WO2001005947A1 Melanin-concentrating hormone receptor |
| 01/25/2001 | WO2001005940A2 Methods for producing and preparing cells for cell therapy |
| 01/25/2001 | WO2001005834A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | WO2001005831A1 Modulation of human sodium channels in dorsal root ganglia |
| 01/25/2001 | WO2001005802A1 Antisense modulation of fadd expression |
| 01/25/2001 | WO2001005793A1 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION |
| 01/25/2001 | WO2001005790A1 New compounds |
| 01/25/2001 | WO2001005783A1 Bradykinin b1 receptor antagonists |
| 01/25/2001 | WO2001005776A1 Aminothiazole derivatives and their use as crf receptor ligands |
| 01/25/2001 | WO2001005772A1 Pyrazinones, compositions containing such compounds |
| 01/25/2001 | WO2001005770A1 Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| 01/25/2001 | WO2001005764A2 Sulfuric acid mono-[3-({1- [2-(4-fluoro-phenyl)-ethyl]- piperidin-4-yl}- hydroxy- methyl)-2- methoxy-phenyl]ester |
| 01/25/2001 | WO2001005758A2 Indoles and indazoles for the treatment of migraine |
| 01/25/2001 | WO2001005756A1 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors |
| 01/25/2001 | WO2001005743A1 3-amino-2-benzyl-1-phenyl-propane derivatives |
| 01/25/2001 | WO2001005428A1 Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| 01/25/2001 | WO2001005422A2 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 01/25/2001 | WO2001005418A2 Tissue regenerating agent |
| 01/25/2001 | WO2001005410A1 Neurotropic virus transport |
| 01/25/2001 | WO2001005404A1 Use of beta-napthoquinone for making medicines having an inhibiting effect on the release of glutamate by the brain |
| 01/25/2001 | WO2001005393A2 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | WO2001005392A2 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | WO2001005391A2 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | WO2001005390A2 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | WO2001005385A2 New use of a macrolide compound for treating neurodegenerative disorders |
| 01/25/2001 | WO2000067739A3 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
| 01/25/2001 | WO2000066587A3 Polyamines and their use in therapy |
| 01/25/2001 | WO2000061176A3 Treatment of multiple sclerosis with a combination of interferon and growth hormone |
| 01/25/2001 | WO2000061171A3 Uses of mammalian ox2 protein and related reagents |
| 01/25/2001 | WO2000061156A3 Methods of treating schizophrenia |
| 01/25/2001 | WO2000059946A8 Hydroxymatairesinol in cancer prevention |
| 01/25/2001 | WO2000058473A3 Nucleic acids including open reading frames encoding polypeptides; 'orfx' |
| 01/25/2001 | WO2000056356A3 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs) |
| 01/25/2001 | WO2000054815A3 Expression of dna or proteins in c. elegans |
| 01/25/2001 | WO2000054756A3 Nitrate esters and their use for introducing neuroprotection and cognition enhancement |
| 01/25/2001 | WO2000051577A3 Use of fluorinated triazoles for treating pain and affective or attention disorders |
| 01/25/2001 | DE19934433A1 New N-(indolyl-carbonyl)-N'-ethyl-piperazine derivatives, are 5-HT-2A receptor antagonists useful e.g. for treating schizophrenia, depression, Parkinson's disease, Alzheimer's disease or anorexia |
| 01/25/2001 | DE19933421A1 2-Benzyl-3-dimethylamino-1-phenyl-propanderi- vate 2-benzyl-3-dimethylamino-1-phenyl-propanderi- derivatives |
| 01/25/2001 | CA2616704A1 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 01/25/2001 | CA2381961A1 Splice variants of cd40-receptor |
| 01/25/2001 | CA2381327A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | CA2379968A1 Gtp-binding protein associated factors |
| 01/25/2001 | CA2379554A1 Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| 01/25/2001 | CA2379391A1 Modulation of human sodium channels in dorsal root ganglia |
| 01/25/2001 | CA2379336A1 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 01/25/2001 | CA2379140A1 Use of a tacrolimus analogue as a neuroprotective agent |
| 01/25/2001 | CA2379064A1 Bradykinin b1 receptor antagonists |
| 01/25/2001 | CA2378930A1 Electron transfer proteins |
| 01/25/2001 | CA2378917A1 Melanin-concentrating hormone receptor |
| 01/25/2001 | CA2378723A1 3-amino-2-benzyl-1-phenyl-propane derivatives |
| 01/25/2001 | CA2378381A1 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | CA2378202A1 New compounds |
| 01/25/2001 | CA2378047A1 Heterocyclic compounds for the treatment of migraine |
| 01/25/2001 | CA2377906A1 Methods for producing and preparing cells for cell therapy |
| 01/25/2001 | CA2377718A1 1,2,3,4,5,6-hexahydroazepino¬4,5-b|indoles containing arylsulfones at the 9-position |
| 01/25/2001 | CA2377100A1 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | CA2377092A1 Method for treating chronic pain using mek inhibitors |
| 01/25/2001 | CA2375458A1 Compositions and methods for the treatment of immune related diseases |
| 01/25/2001 | CA2374052A1 Method for treating chronic pain using mek inhibitors |
| 01/24/2001 | EP1070716A1 Beta-carboline derivatives, process for their preparation and pharmaceutical compositions containing them |
| 01/24/2001 | EP1070708A1 Triazole and imidazole derivatives |
| 01/24/2001 | EP1070502A2 Compositions and methods for treating or preventing inflammatory diseases |
| 01/24/2001 | EP1070501A1 Method of preparing a dispersible fluoxetine tablet |
| 01/24/2001 | EP1070262A1 Pharmacological mri (phmri) |
| 01/24/2001 | EP1070141A1 Immediate early genes and methods of use therefor |
| 01/24/2001 | EP1070083A1 Crystalline forms of 1s- 1alpha (2s*,3r*), 9alpha]-6, 10-dioxo-n- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl) -9- (1-isoquinolyl) carbonyl]-amino] octahydro-6h -piridazino 1, 2-a] 1,2] diazepin- 1-carboxamide |
| 01/24/2001 | EP1070069A1 Bicyclic hydroxamic acid derivatives |
| 01/24/2001 | EP1070066A1 SUBSTITUTED 1,2,4-TRIAZOLO 3,4-a]PYRIDAZINE |
| 01/24/2001 | EP1070065A1 Azabicyclic 5ht1 receptor ligands |
| 01/24/2001 | EP1070064A1 Antagonists of gonadotropin releasing hormone |
| 01/24/2001 | EP1070063A1 Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists) |
| 01/24/2001 | EP1070058A1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides |
| 01/24/2001 | EP1070051A1 Process for the production of r-(+)-6- carboxamido- 3-n- methylamino- 1,2,3,4- tetrahydrocarbazole |
| 01/24/2001 | EP1070050A1 N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents) |
| 01/24/2001 | EP1069900A1 Use of reboxetine for the treatment of neuropsychiatric disorders |
| 01/24/2001 | EP1069899A1 Treatment of panic attacks |
| 01/24/2001 | EP1069893A2 Use of dexmedetomidine for icu sedation |
| 01/24/2001 | EP1069892A1 Therapeutic system which can be moisture-activated |
| 01/24/2001 | EP0788513B1 Use of binding agents to cd23 in the treatment of autoimmune diseases |
| 01/24/2001 | EP0706523B1 Substituted arylthioalkylthiopyridines |
| 01/24/2001 | EP0689439B1 Use of triazine compounds in the preparation of a medicament for the treatment of memory and learning disorders |
| 01/24/2001 | EP0573568B1 Use of nicotinic analogs for treatment of degenerative diseases of the nervous system |
| 01/24/2001 | CN1281459A Piperidine derivatives |
| 01/24/2001 | CN1281458A Purine compounds having PDE IV inhibitory activity and methods of synthesis |
| 01/24/2001 | CN1281455A 8-Azabicyclo [3,2,1] octane-3-methanamine derivatives as ligands of D2 and D3 dopamine and 5HT1A and 5HT2 serotonin receptors |
| 01/24/2001 | CN1281451A Benzamine derivatives |
| 01/24/2001 | CN1281448A Process for preparation of paroxetine hydrochloride |
| 01/24/2001 | CN1281443A Bicyclic compounds, process for their preparation and pharmaceutical composition containing them |
| 01/24/2001 | CN1281442A Novel compounds useful as neuro-protective agents |
| 01/24/2001 | CN1281430A N-alkanoylphenylalanine derivatives |
| 01/24/2001 | CN1281429A Novel aryloxy-alkyl-dialkylamines |
| 01/24/2001 | CN1281366A Prevention and treatment of amyloidogenic disease |
| 01/24/2001 | CN1281357A Medicaments |
| 01/24/2001 | CN1281335A Treatment of schizophrenia with ampakines and neuroleptics |
| 01/24/2001 | CN1281334A Method for treating Alzheimer's disease |
| 01/24/2001 | CN1280827A Sigma receptor action medicine containing alkaloid |
| 01/24/2001 | CN1280825A Sigma-receptor acting medicine containing protopine-type alkaloid |